| [1] |
Bray F, Ferlay J, Soerjomataram I, et al. Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries[J]. CA Cancer J Clin, 2018, 68(6):394-424.
|
| [2] |
Rook GA，Dalgleish A. Infection,immunoregulation,and cancer[J]. Immunol Rev, 2011, 240(1):141-159.
|
| [3] |
Chaturvedi VK, Singh A, Dubey SK, et al. Molecular mechanistic insight of hepatitis B virus mediated hepatocellular carcinoma[J]. Microb Pathog, 2019, 128(3):184-194.
|
| [4] |
Yu LX, Schwabe RF. The gut microbiome and liver cancer; mechanisms and clinical translation[J]. Nat Rev Gastroenterol Hepatol, 2017, 14(9):527-539.
|
| [5] |
Zhou TY, Zhou YL, Qian MJ, et al. Interleukin-6 induced by YAP in hepatocellular carcinoma cells recruits tumor-associated macrophages[J]. J Pharmacol Sci, 2018, 138(2):89-95.
|
| [6] |
Zhou X, Li W, Wang S, et al. YAP aggravates inflammatory bowel disease by regulating M1/M2 macrophage polarization and gut microbial homeostasis[J]. Cell Rep, 2019, 27(4):1176-1189, e5.
|
| [7] |
Wang Z, Yan M, Li J，et al. Dual functions of STAT3 in LPS-induced angiogenesisof hepatocellular carcinoma[J]. Biochim Biophys Acta Mol Cell Res, 2019, 1866(4):566-574.
|
| [8] |
Dong YQ, Lu CW, Zhang L，et al. Toll-like receptor 4 signaling promotes invasion of hepatocellular carcinoma cells through MKK4/JNK pathway[J]. Mol Immunol, 2015, 68(2 Pt C):671-683.
|
| [9] |
Lu Y, Xu J, Chen S, et al. Lipopolysaccharide promotes angiogenesis in mice model of HCC by stimulating hepatic stellate cell activation via TLR4 pathway[J]. Acta Biochim Biophys Sin, 2017, 49(11):1029-1034.
|
| [10] |
Yi L, Huang X, Guo F, et al. Lipopolysaccharide induces human pulmonary micro-vascular endothelial apoptosis via the YAP signaling pathway[J]. Front Cell Infect Microbiol, 2016(6):133.
|
| [11] |
Wang G, Lu X, Dey P, et al. Targeting YAP-dependent MDSC infiltration impairs tumor progression[J]. Cancer Discov, 2016, 6(1): 80-95.
|
| [12] |
Fan Z, Xia H, Xu H, et al. Standard CD44 modulates YAP1 through a positive feedback loop in hepatocellular carcinoma[J]. Biomed Pharmacother, 2018, 103:147-156.
|
| [13] |
Noce V, Battistelli C, Cozzolino AM, et al.YAP integrates the regulatory Snail/HNF4α circuitry controlling epithelial/hepatocyte differentiation[J]. Cell Death Dis, 2019, 10(10):768.
|
| [14] |
Guo X, Zhao Y, Yan H, et al. Single tumor-initiating cells evade immune clearance by recruiting type II macrophages[J]. Genes Dev, 2017, 31(3):247-259.
|
| [15] |
Yang L, Zhang Y. Tumor-associated macrophages: from basic research to clinical application[J]. J Hematol Oncol, 2017, 10(1):58.
|
| [16] |
Biswas SK, Allavena P, Mantovani A. Tumor-associated macrophages: functional diversity, clinical significance, and open questions[J]. Semin Immunopathol, 2013, 35(5):585-600.
|
| [17] |
Yeung OW, Lo CM, Lin CC. et al. Alternatively activated (M2) macrophages promote tumour growth and invasiveness in hepatocellular carcinoma[J]. J Hepatol, 2015, 62(3):607-616.
|
| [18] |
Huang YJ, Yang CK, Wei PL, et al. Ovatodiolide suppresses colon tumorigenesis and prevents polarization of M2 tumor-associated macrophages through YAP oncogenic pathways[J]. J Hematol Oncol, 2017, 10(1):60.
|
| [19] |
Lee PC, Machner MP. The legionella effector kinase LegK7 hijacks the host Hippo pathway to promote infection[J]. Cell Host Microbe, 2018, 24(3):429-438.
|
| [20] |
Bouhlel MA, Derudas B, Rigamonti E, et al. PPAR gamma activation primes human monocytes into alternative M2 macrophages with anti-inflammatory properties[J]. Cell Metab, 2007, 6(2):137-143.
|